| 7.11 -1 (-12.33%) | 10-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.84 | 1-year : | 11.5 |
| Resists | First : | 8.43 | Second : | 9.84 |
| Pivot price | 5.22  |
|||
| Supports | First : | 4.71 | Second : | 2.42 |
| MAs | MA(5) : | 7.61 | MA(20) : | 4.91 |
| MA(100) : | 3.48 |
MA(250) : | 7.55 |
|
| MACD | MACD : | 1 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 88.3 |
D(3) : | 91.3 |
| RSI | RSI(14): 66 |
|||
| 52-week | High : | 22 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ YDES ] has closed below upper band by 26.8%. Bollinger Bands are 332% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.04 - 8.08 | 8.08 - 8.12 |
| Low: | 6.75 - 6.79 | 6.79 - 6.83 |
| Close: | 7.04 - 7.11 | 7.11 - 7.17 |
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Fri, 04 Sep 2026
YD Bio Limited (YDES) Edges Higher as Shares Hold Above Key Support - Price Momentum Stocks - dars.gov.et
Wed, 10 Sep 2025
YD Bio (Nasdaq:YDES) - Stock Analysis - Simply Wall Street
Fri, 29 Aug 2025
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market - PR Newswire
Thu, 28 Aug 2025
YD Bio Ltd (YDES) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 27 Aug 2025
BREEZE HLDGS ACQ WTS (BRZHW) Stock Price, News & Analysis - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 80.1 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.57 |
| Profit Margin | -276.6 % |
| Operating Margin | -444.6 % |
| Return on Assets (ttm) | -25.5 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 95.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 986.75 |
| Price to Cash Flow | -273.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|